iBio, Inc. announced an exclusive agreement with AstralBio to license a long-acting anti-myostatin antibody ... iBio’s strategy to enhance its pipeline with advanced therapeutics that promote ...

In China and South Korea, ABL Bio and I-Mab share joint rights. "I-Mab pauses CD73 antibody development in pipeline reshuffle" was originally created and published by Clinical Trials Arena ...

The Chinese company is deploying the technology in its in-house pipeline in AG126, an antibody prodrug targeting the immune checkpoint CTLA4. That's the same target as Bristol-Myers Squibb's ...

LEBANON, N.H., January 14, 2025--(BUSINESS WIRE)--Adimab, LLC, the global leader in the discovery and engineering of fully human monoclonal and multispecific antibodies, today announced that five ...

NAYA Biosciences has announced the expansion of its bifunctional antibody pipeline to include a novel PD-1 x VEGF tetravalent antibody, NY-500, targeted at hepatocellular carcinoma (HCC ...

ImmunoPrecise Antibodies (IPA) announced the launch of its AI-powered pipeline of both optimized and new therapeutics. By combining advanced artificial intelligence with first-principles thinking ...

complementing the Company’s anti-CD19 antibody, budoprutug. "Adding CLYM116 to our pipeline represents a pivotal moment for Climb Bio as we advance our ambition of becoming a leader in ...

By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs.